# Phase Ib Study of Efsubaglutide Alfa Injection in Obese Adolescents

> **NCT07693426** · PHASE1 · RECRUITING · sponsor: **Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.** · enrollment: 36 (estimated)

## Conditions studied

- Adolescence Obesity

## Interventions

- **DRUG:** Efsubaglutide Alfa 5 mg QW
- **DRUG:** Efsubaglutide Alfa 10 mg QW
- **DRUG:** Efsubaglutide Alfa 20 mg QW
- **DRUG:** Efsubaglutide Alfa placebo

## Key facts

- **NCT ID:** NCT07693426
- **Lead sponsor:** Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-16
- **Primary completion:** 2027-04-30
- **Final completion:** 2027-08-31
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07693426

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07693426, "Phase Ib Study of Efsubaglutide Alfa Injection in Obese Adolescents". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07693426. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*